Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00553
|
|||||
Drug Name |
Ceftriaxone
|
|||||
Synonyms |
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate; (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid; Biotrakson; CEFTRIAXONE SODIUM; CTRX; Cefatriaxone; Ceftriaxon; Ceftriaxona; Ceftriaxona [INN-Spanish]; Ceftriaxone (INN); Ceftriaxone (TN); Ceftriaxone [USAN:JAN]; Ceftriaxone intravenous; Ceftriaxone, Disodium Salt; Ceftriaxone, Disodium Salt, Hemiheptahydrate; Ceftriaxonum; Ceftriaxonum [INN-Latin]; Ceftriazone; DRG-0071; Longacef; Longaceph; Ro 139904; Ro-13-9904; Ro13-9904; Rocefin; Rocephin; Rocephin (TN); Rocephine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Pneumonia [ICD11: CA40] | Approved | [1] | |||
Middle ear infections [ICD11: AB0Z] | Approved | [1] | ||||
Endocarditis [ICD11: 1B41.1] | Approved | [1] | ||||
Meningitis [ICD11: 1D01.Y] | Approved | [1] | ||||
Therapeutic Class |
Antibiotics
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C18H18N8O7S3
|
|||||
Canonical SMILES |
CN1C(=NC(=O)C(=O)N1)SCC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
|
|||||
InChI |
InChI=1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
|
|||||
InChIKey |
VAAUVRVFOQPIGI-SPQHTLEESA-N
|
|||||
CAS Number |
CAS 73384-59-5
|
|||||
Pharmaceutical Properties | Molecular Weight | 554.6 | Topological Polar Surface Area | 288 | ||
Heavy Atom Count | 36 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 13 | |||
XLogP |
-1.3
|
|||||
PubChem CID | ||||||
PubChem SID |
103240795
, 103980019
, 113985965
, 11693489
, 124766008
, 126631063
, 126657477
, 134224100
, 134337467
, 134338568
, 135011808
, 137019029
, 140116145
, 141914537
, 14886134
, 14935103
, 152100037
, 15968575
, 160964545
, 162178862
, 175265409
, 176267075
, 179151046
, 179323748
, 196109964
, 210279827
, 210282150
, 223653569
, 223680127
, 223680436
, 226412100
, 241132770
, 250133954
, 252122133
, 39470230
, 46506458
, 48415733
, 50050959
, 51091963
, 57363926
, 602917
, 7978887
, 79861798
, 87322639
, 8908
, 92711237
|
|||||
ChEBI ID |
CHEBI:3441
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [2] | |
OATP1B3 | Transporter Info | Organic anion transporting polypeptide 1B3 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | ||
PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [4] | ||
References | ||||||
1 | Ceftriaxone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
3 | Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull. 2011;34(3):389-95. | |||||
4 | Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.